A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors

Status:	Recruiting
Conditions:	Lung Cancer, Prostate Cancer, Cancer, Cancer, Cancer
Therapuetic Areas:	Oncology
Healthy:	No
Age Range:	18 - Any
Updated:	4/5/2019
Start Date:	February 21, 2018
End Date:	February 18, 2022
Contact:	There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
Email:	clinicaltrials.gov@lilly.com
Phone:	1-317-615-4559

A Phase 1a/1b Study of an Anti-IDO-1 Agent (LY3381916) Administered Alone or in Combination With Anti- PD-L1 Checkpoint Antibody (LY3300054) in Solid Tumors

The purpose of this study is to evaluate the safety of the study drug LY3381916 administered
alone or in combination with anti-programmed cell death ligand 1 (PD-L1) checkpoint antibody
(LY3300054).

Inclusion Criteria:

- Participant must have histological or cytological evidence of a diagnosis of cancer
that is advanced and/or metastatic.

- Have adequate organ function.

- Have a performance status (PS) of ≤1 on the Eastern Cooperative Oncology Group (ECOG)
scale.

- Have discontinued previous treatments for cancer.

- Are able to swallow capsules.

Exclusion Criteria:

- Currently enrolled in a clinical study.

- Have a serious concomitant systemic disorder.

- Have a symptomatic human immunodeficiency virus infection or symptomatic
activated/reactivated hepatitis B or C.

- Have a significant cardiac condition.

- Have previously received an indoleamine- 2,3-dioxygenase (IDO) inhibitor.

We found this trial at

sites

Institut Jules Bordet

121 Boulevard de Waterloo
Brussel, 1000

Principal Investigator: Nuria Kotecki

Phone: 3225413059

from

Brussel,